Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - levodopa, quantity: 75 mg; carbidopa monohydrate, quantity: 20.25 mg (equivalent: carbidopa, qty 18.75 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: sodium sulfate; hyprolose; carmellose sodium; microcrystalline cellulose; magnesium stearate; trehalose dihydrate; powdered cellulose; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - levodopa, quantity: 200 mg; carbidopa monohydrate, quantity: 54 mg (equivalent: carbidopa, qty 50 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: powdered cellulose; microcrystalline cellulose; sodium sulfate; carmellose sodium; magnesium stearate; hyprolose; trehalose dihydrate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - levodopa, carbidopa, entacapone - film coated tablet - 50/12.5/200 milligram - dopa and dopa derivatives dopa and dopa derivatives

Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - levodopa, carbidopa, entacapone - film coated tablet - 75/18.75/200 milligram - dopa and dopa derivatives dopa and dopa derivatives

Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - levodopa, carbidopa, entacapone - film coated tablet - 100/25/200 milligram - dopa and dopa derivatives dopa and dopa derivatives

Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - levodopa, carbidopa, entacapone - film coated tablet - 125/31.25/200 milligram - dopa and dopa derivatives dopa and dopa derivatives

Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - levodopa, carbidopa, entacapone - film coated tablet - 150/37.5/200 milligram - dopa and dopa derivatives dopa and dopa derivatives

Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - levodopa, carbidopa, entacapone - film coated tablet - 175/43.75/200 milligram - dopa and dopa derivatives dopa and dopa derivatives

Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - levodopa, carbidopa, entacapone - film coated tablet - 200/50/200 milligram - dopa and dopa derivatives dopa and dopa derivatives

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - levodopa, quantity: 200 mg; carbidopa monohydrate, quantity: 54.1 mg (equivalent: carbidopa, qty 50 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose; hyprolose; povidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; glycerol; iron oxide yellow; polysorbate 80; iron oxide red; iron oxide black - lecteva (levodopa/carbidopa/entacapone) is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.